[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cardiovascular-risk-factors\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cardiovascular-risk-factors":551},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,19,0,[8,44,70,98,127,160,189,219,251,282,310,343,372,400,424,446,471,498,518],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":27,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100644470",false,"NCT07670741","Community Blood Pressure Screening and Cardiovascular Risk Assessment in Croatia","A Prospective Observational Study of Blood Pressure Values, Antihypertensive Medication Use and Cardiovascular Risk Factors Among Adults Attending Community-Based Public Health Screening Campaigns in Croatia","BPSCREEN-CRO","Inclusion Criteria:\n\n* Age 18 years or older\n* Voluntary attendance at a community-based public health blood pressure screening campaign\n* Ability to understand the study information\n* Signed informed consent for participation in the baseline observational study\n\nExclusion Criteria:\n\n* Age under 18 years\n* Inability or unwillingness to provide informed consent\n* Incomplete baseline blood pressure data preventing assessment of the primary outcome\n* Acute medical condition requiring immediate emergency evaluation before completion of study procedures, at the discretion of the research team",true,"ALL","18 Years",{"count":20,"type":21},500,"ESTIMATED","OBSERVATIONAL","This is a prospective, observational, non-interventional study conducted during community-based public health blood pressure screening campaigns in Croatia. Adult participants who voluntarily attend public health actions will be invited to complete a short questionnaire on demographics, known cardiovascular risk factors, medical history and medication use. Blood pressure and pulse will be measured using validated blood pressure monitors. The study will assess the prevalence of elevated blood pressure, known and potentially undiagnosed hypertension, antihypertensive treatment patterns and cardiovascular risk factors. Participants may optionally consent to short-term follow-up by telephone or e-mail after 1 to 3 months to collect information on repeated blood pressure measurement, physician consultation, additional evaluation, new diagnosis of hypertension or medication change. The study does not include treatment allocation, prescribing or modification of therapy by the research team.",[25,26],"Hypertension","Cardiovascular Risk Factors",[28,29,30],"blood pressure screening","public health campaign","antihypertensive medication","NOT_YET_RECRUITING","2026-06-25",{"date":34,"type":35},"2026-06-29","ACTUAL",{"date":37,"type":21},"2026-07-15",{"date":39,"type":21},"2028-07-15",{"name":41,"class":42},"Dr. Josip Benčević General Hospital","OTHER",1,{"id":45,"slug":4,"hasResults":10,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":10,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":53,"briefSummary":55,"conditions":56,"keywords":58,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":43},"100624019","NCT07404189","Augmenting Primary Care-Based Obesity Management With the Nutu™ Digital Health Platform","Evaluation of the Acceptability and Clinical Effectiveness of Augmenting Comprehensive Primary Care-Based Obesity Management With the Nutu™ Digital Health Platform","Inclusion Criteria:\n\n* All patients enrolled in the FLOW clinical program are eligible.\n\nExclusion Criteria:\n\n* Not a patient of the FLOW clinical program at UAB.",{"count":51,"type":21},300,"INTERVENTIONAL",[54],"NA","This study evaluates the acceptability and clinical effectiveness of integrating the Nutu™ digital health platform into a comprehensive primary care-based behavioral obesity treatment program using a Zelen randomized controlled trial design.",[57,26],"Obesity & Overweight",[59,60,61],"intensive behavioral therapy","digital health coaching","weight management","2026-06-22",{"date":32,"type":35},{"date":65,"type":21},"2026-08",{"date":67,"type":21},"2028-06",{"name":69,"class":42},"University of Alabama at Birmingham",{"id":71,"slug":4,"hasResults":10,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":10,"sex":17,"minAge":18,"maxAge":77,"enrollmentInfo":78,"targetDuration":80,"studyType":22,"phases":4,"briefSummary":81,"conditions":82,"keywords":86,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":43},"100464991","NCT05334888","Sex-differential Host-microbiome CVD Risk - A Longitudinal Cohort Approach","Sex Hormone-specific Cardiovascular Risks in the Gut Microbiome-host Axis - A Longitudinal Cohort Study.","XCVD","Inclusion Criteria:\n\n* Age 18-50\n* Language requirements: German, English\n* Previous gender hormone replacement therapy (HRT).\n* Ability to give consent and written consent to participate.\n* Health insurance (for clarification of incidental findings)\n\nExclusion Criteria:\n\n* Diseases or functional disorders that, in the opinion of the study physician, preclude participation in the study.\n* Incapacity or other circumstances that do not allow study participants to fully understand the nature, significance and scope of this study.","50 Years",{"count":79,"type":21},200,"2 Years","The XCVD study investigates the influence of sex hormones on the composition of the gut microbiome and the possible emergence of cardiovascular risk factors. It will follow 200 healthy transgender individuals for five years during their hormone replacement therapy (HRT) and analyze them for the possible emergence of cardiovascular risk factors in relation to changes in the gut microbiome, metabolome, and immunome. We would also like to phenotype cardiovascular disease.",[83,84,85,26],"Transgender","Gut Microbiome","Immune System",[87],"Transgender Medicine","RECRUITING","2026-06-12",{"date":91,"type":35},"2026-06-15",{"date":93,"type":35},"2022-08-29",{"date":95,"type":21},"2030-12-31",{"name":97,"class":42},"Charite University, Berlin, Germany",{"id":99,"slug":4,"hasResults":10,"nctId":100,"briefTitle":101,"officialTitle":101,"acronym":102,"eligibilityCriteria":103,"healthyVolunteers":10,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":104,"targetDuration":4,"studyType":52,"phases":105,"briefSummary":106,"conditions":107,"keywords":112,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":43},"100585860","NCT06907862","The SWITCH (Substitution of High With Low Ultra-processed Soy Protein Foods In a Guideline-based Diet inTervention for Cardiometabolic Health) Trial","SWITCH","Inclusion Criteria:\n\n* Obesity (BMI and waist circumference using sex and ethnic-specific thresholds for obesity and significant abdominal adiposity)\n* adults (≥18years)\n* hypertension (SBP 120-160 mmHg)\n* on stable antihypertensive, antihyperglycemic, antihyperlipidemic, or anti-obesity medications (≥3-months)\n* not planning new weight loss for the duration of the trial\n* 50% living with type 2 diabetes, HbA1c 6.5-9.0%\n\nExclusion Criteria:\n\n* Individuals with a history of major cardiovascular events in the last year (stroke or myocardial infarction)\n* type 1 diabetes diagnosis\n* recent weight loss or weight gain (≥5% over \\\u003C6 months)\n* current treatment with insulin\n* eating disorders; substance abuse disorders\n* serious depression or psychiatric disorders\n* bariatric or recent surgery (\\\u003C6 months)\n* uncontrolled hypertension (SBP\u002FDBP \\>160\u002F100 mmHg)\n* angina pectoris\n* gastrointestinal and malabsorption disorders (i.e. inflammatory bowel disease, celiac), pancreatitis, chronic kidney or liver disease, cardiac condition that compromises normal function (e.g. mitral valve disease, heart failure), major disability or disorder requiring continuous medical attention.\n* herb or supplement use that may affect primary outcome.\n* alcohol use \\>3 drinks\u002Fday; participation in another trial.\n* allergies\u002Fintolerances to soy; allergies\u002Fintolerances to tree nuts, peanuts and seeds (the combination of all 3).\n* chronic or prescribed use of certain medications including prescription high dose NSAIDs, antacids, warfarin, medications affecting NO synthesis (i.e. sildenafil, organic nitrates, etc.)\n* acute or chronic infection (e.g. active HIV, TB, COVID-19, chronic inflammatory infections)\n* chronic inflammatory condition (such as rheumatoid arthritis)\n* use of antibiotics within 3-months of the study start",{"count":51,"type":21},[54],"This is a randomized, controlled, parallel study with 3 experimental arms aimed to assess the effect of a digital dietary intervention (web-based app, online behavior change curriculum) enhanced with 10 servings of vegetables and fruit (5 as dietary advice within the app, 5 within a dehydrated vegetable and fruit blend), with or without high Ultra Processed Food (UPF) soy-containing proteins compared to standard of care (usual care) on systolic blood pressure (SBP; primary outcome), and other key cardiometabolic endpoints over 12-weeks in adults living with hypertension and obesity, 50% with type 2 diabetes. The main questions this study aims to answer are:\n\n1. Are nutrient-dense, high-UPF soy-protein foods similar (non-inferior) to low-UPF soy-protein foods in the context of a guidelines-based diet in their effect on blood pressure and other cardiometabolic risk factors?\n2. Does an enhanced digital dietary intervention lead to meaningful reductions in blood pressure and other cardiometabolic risk factors compared to standard of care?\n\nParticipants who are eligible and consent to be part of this study will be randomized to one of the following groups: 1) Active treatment (high-UPF soy-containing enhanced digital dietary intervention), 2) Reference treatment (low-UPF soy-containing enhanced digital dietary intervention), or 3) Control (standard of care).\n\nParticipant Requirements:\n\nDuring the 12-week intervention, all participants will be required to attend in-person clinic visits at baseline (week 0), week 8 and 12.\n\nBaseline Visit (Week 0): Participants will be asked to arrive in a fasted state (no food or beverages, except water, for 10-12 hours before the visit).\n\n* Undergo various assessments, including anthropometric measurements, office blood pressure readings, and blood sampling (via a capillary finger prick and blood sample taken by the study nurse).\n* Review the 7-day food records completed using the Keenoa mobile app one week prior to clinic visit.\n* Bring fecal and urine samples from home.\n* Complete and review all questionnaires received via email one week prior.\n\nTelephone Check-in (Week 1):\n\nOne week after beginning the study, the study staff will call participants to check in on how participants are following the protocol and answer any questions.\n\nMid-Study Visit (Week 8): Participants will be asked to arrive in a fasted state (no food or beverages, except water, for 10-12 hours before the visit).\n\n* Have their office blood pressure and anthropometric measurements taken.\n* Complete and review all questionnaires received via email one week prior\n* Review the 3-day food records completed using the Keenoa mobile app one week prior to clinic visit.\n\nFinal Study Visit (Week 12): Participants will be asked to arrive in a fasted state (no food or beverages, except water, for 10-12 hours before the visit).\n\n* Undergo various assessments, including anthropometric measurements, office blood pressure readings, and blood sampling (via a capillary finger prick and blood sample taken by the study nurse).\n* Review the 7-day food records completed using the Keenoa mobile app one week prior to clinic visit.\n* Bring fecal and urine samples from home.\n* Complete and review all questionnaires received via email one week prior.\n\nThroughout the study, participants will be asked to continue their usual lifestyle and physical activity.\n\nAdditional Requirements for Treatment Groups:\n\nParticipants randomized to the active and reference treatment groups will also be required to:\n\n* Incorporate a study vegetable and fruit blend (provided) into their daily diet for the full 12 weeks\n* Consume soy products categorized as either high ultra processed soy foods at least 4 servings per day, including at least 2 servings of ultra processed soy milk and 2 servings of other soy-based products (e.g., soy yogurt, soy burgers, or soy ground round) or non-ultra processed soy foods at least 4 servings per day, including at least 2 servings of minimally processed soy milk, 1 serving of edamame or roasted soy nuts, and 1 serving of tofu or tempeh\n* Participate in the digital dietary intervention, which includes: a health app, 7-day Kickstart Package, weekly text message support, and a 7-session online interactive program designed based on behaviour change theory\n* Attend a virtual focus group at Week 4 and complete an online feedback questionnaire",[108,109,110,25,111,26],"Hypertension in Type 2 Diabetes","Diabetes Mellitus Type 2","Dyslipidemia","Metabolic Health",[113,25,114,115,116,117],"Randomized controlled trial","Cardiometabolic health","Ultra processed food","technology-based dietary intervention","dehydrated vegetable and fruit blend","2026-04-27",{"date":120,"type":35},"2026-05-04",{"date":122,"type":35},"2025-08-06",{"date":124,"type":21},"2028-06-30",{"name":126,"class":42},"University of Toronto",{"id":128,"slug":4,"hasResults":10,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":132,"eligibilityCriteria":133,"healthyVolunteers":10,"sex":17,"minAge":134,"maxAge":4,"enrollmentInfo":135,"targetDuration":4,"studyType":52,"phases":137,"briefSummary":138,"conditions":139,"keywords":141,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":156,"locationsCount":159},"100601648","NCT07113223","Determining Efficacy of an Artificial Intelligence-based System for Heart Failure Detection Through Interpretation of Electrocardiograms (DECISION)","Determining Efficacy of an Artificial Intelligence-based System for Heart Failure Detection Through Interpretation of Electrocardiograms: a Pragmatic Randomized Clinical Trial (DECISION)","DECISION","Inclusion Criteria:\n\n* Patients with Suspected HF (Group S):\n\n  * Able to understand and accept the study constraints and to provide informed consent (either themselves or a legal representative).\n  * Age over 65 years (i.e., 65 included).\n  * Presence of symptoms and\u002For signs typical of Heart Failure (defined by the European Society of Cardiology, ESC), including breathlessness (during activity or at rest, lying down, waking up at night needing to catch their breath), fatigue, swollen ankles\u002Flegs, and\u002For palpitations.\n* Patients at Risk of Heart Failure due to the presence of cardiovascular (Group R):\n\n  * Able to understand and accept the study constraints and to provide informed consent (either themselves or a legal representative).\n  * Age over 65 years (i.e., 65 included).\n  * Absence of symptoms and\u002For signs typical of Heart Failure (defined by the ESC), including breathlessness (during activity or at rest, lying down, waking up at night needing to catch their breath), fatigue, swollen ankles\u002Flegs, and\u002For palpitations.\n  * Presence of at least 1 ACC\u002FAHA Heart Failure risk factor, including hypertension, cardiovascular disease (atrial fibrillation, coronary heart disease or stroke), diabetes, obesity, exposure to cardiotoxic agents, genetic variant for cardiomyopathy, or family history of cardiomyopathy that requires an ECG test for any reason in a primary care center or with an indication of a regular health examination where an ECG is included.\n\nExclusion Criteria:\n\n* Unwillingness or inability to sign the written informed consent.\n* Previous Heart Failure diagnosis.\n* Unavailability or suboptimal quality ECG.","65 Years",{"count":136,"type":21},1968,[54],"The DECISION trial aims to evaluate the efficacy of an artificial intelligence (AI)-powered system, Willem™, for improving the detection of heart failure (HF) in primary care settings by interpreting electrocardiograms (ECGs). The study seeks to answer whether AI-assisted ECG interpretation enhances diagnostic accuracy and clinical outcomes compared to standard ECG evaluation in patients with suspected HF or those at high risk.\n\nThis multicenter, pragmatic, randomized clinical trial involves two groups: patients receiving AI-assisted ECG analysis and those undergoing standard ECG evaluation. The study's primary analysis will compare the diagnostic performance of AI-assisted ECG versus standard ECG using sensitivity, specificity, and predictive value metrics. Secondary analyses will evaluate healthcare resource utilization, clinical outcomes, and usability feedback from healthcare providers. Results will inform the potential integration of AI-assisted ECG in routine primary care workflows for earlier HF detection and better resource allocation.",[140,26],"Heart Failure",[140,142,143,144,145,146,147,148],"Artificial Intelligence","Electrocardiogram (ECG)","Primary Care","Diagnostic Tools","Cardiology","Electrocardiography","Risk Stratification","2026-03-30",{"date":151,"type":35},"2026-03-31",{"date":153,"type":35},"2025-07-23",{"date":155,"type":21},"2026-09",{"name":157,"class":158},"Idoven 1903 S.L.","INDUSTRY",5,{"id":161,"slug":4,"hasResults":10,"nctId":162,"briefTitle":163,"officialTitle":164,"acronym":4,"eligibilityCriteria":165,"healthyVolunteers":16,"sex":166,"minAge":167,"maxAge":168,"enrollmentInfo":169,"targetDuration":4,"studyType":52,"phases":171,"briefSummary":172,"conditions":173,"keywords":176,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":180,"lastUpdatePostDateStruct":181,"startDateStruct":182,"completionDateStruct":184,"leadSponsor":186,"locationsCount":43},"100631609","NCT07502911","The Effect of Women's Heart Health Awareness Program","The Effect of a Heart Health Awareness Program on Women's Knowledge, Attitudes, and Practice Toward Cardiovascular Disease and Health Literacy: A Single-Blind Cluster Randomized Controlled Trial","Inclusion Criteria:\n\n* Being female,\n* Aged between 20 and 64 years (inclusive),\n* Being literate,\n* Regularly attending any course at the Family Center,\n* Active user of the WhatsApp application.\n\nExclusion Criteria:\n\n* Being an immigrant with a Turkish language barrier (unable to communicate in Turkish),\n* Being pregnant,\n* Being in the postpartum period,\n* Having a prior diagnosis of any cardiovascular disease,\n* Having a prior diagnosis of any type of cancer.","FEMALE","20 Years","64 Years",{"count":170,"type":21},207,[54],"The aim of this study is to examine the effect of a gender-specific heart health protection awareness program, incorporating video-supported reminder messages, on knowledge, attitudes, practices (KAP) regarding cardiovascular diseases and health literacy among adult women aged 20 to 64 with no prior diagnosis of cardiovascular disease. The centers where the study is conducted will be divided into intervention (n=4) and control (n=5) groups using cluster randomization. While the intervention group receives a heart health awareness program consisting of three sessions in total, including education, risk factor screening, and individual counseling over a period of three weeks, the control group will receive standard of care. Data will be collected at the beginning of the first session and after the completion of the final session.",[174,26,175],"Cardiovascular Health","Health Literacy",[177,178,179],"Cardiovascular diseases","women's health","health literacy","2026-03-25",{"date":151,"type":35},{"date":183,"type":21},"2026-04-06",{"date":185,"type":21},"2026-04-20",{"name":187,"class":188},"Lokman Hekim University","OTHER_GOV",{"id":190,"slug":4,"hasResults":10,"nctId":191,"briefTitle":192,"officialTitle":193,"acronym":194,"eligibilityCriteria":195,"healthyVolunteers":10,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":196,"targetDuration":4,"studyType":52,"phases":198,"briefSummary":199,"conditions":200,"keywords":205,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":210,"lastUpdatePostDateStruct":211,"startDateStruct":213,"completionDateStruct":215,"leadSponsor":217,"locationsCount":43},"100627340","NCT07447362","Clinical Management of Cardiovascular Risk Factors in Adult Patients: A Before-and-After Interventional Study","Effect of a Structured Clinical and Pharmacological Management Strategy on Cardiovascular Risk Factors in Adult Patients in Routine Clinical Practice: A Pseudo-Experimental Before-and-After Study","CV-RISK","Inclusion Criteria:\n\n* Age ≥18 years\n* Presence of at least one cardiovascular risk factor (hypertension, diabetes, dyslipidemia, obesity, or smoking)\n* Receiving outpatient clinical follow-up\n* Ability to provide informed consent\n\nExclusion Criteria:\n\n* Severe clinical instability requiring hospitalization\n* Pregnancy\n* End-stage renal disease or dialysis\n* Inability to complete follow-up visits\n* Refusal to participate",{"count":197,"type":21},220,[54],"This study aims to evaluate cardiovascular risk factors, clinical characteristics, and outcomes in adult patients attending an outpatient cardiology clinic. The research focuses on identifying predictors of adverse cardiovascular events, optimizing risk stratification, and improving preventive strategies in routine clinical practice. Data will be collected from patients receiving standard cardiology care without altering their treatment. The results are expected to contribute to better understanding of cardiovascular risk profiles and to support improvements in clinical decision-making and patient management.",[26,25,110,201,202,203,204],"Type 2 Diabetes Mellitus","Obesity","Overweight","Tobacco Use",[206,207,208,209],"Cardiovascular prevention","Risk factor control","Medication adherence","Clinical follow-up","2026-02-27",{"date":212,"type":35},"2026-03-03",{"date":214,"type":35},"2024-07-24",{"date":216,"type":21},"2026-10-24",{"name":218,"class":42},"Universidad Católica San Antonio de Murcia",{"id":220,"slug":4,"hasResults":10,"nctId":221,"briefTitle":222,"officialTitle":222,"acronym":4,"eligibilityCriteria":223,"healthyVolunteers":10,"sex":17,"minAge":224,"maxAge":168,"enrollmentInfo":225,"targetDuration":4,"studyType":52,"phases":227,"briefSummary":228,"conditions":229,"keywords":233,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":242,"lastUpdatePostDateStruct":243,"startDateStruct":245,"completionDateStruct":247,"leadSponsor":249,"locationsCount":43},"100453468","NCT05184933","Sleep and Circadian Mechanisms in Hypertension","Inclusion Criteria:\n\n* Ages 25-64\n* BMI 18.5-42kg\u002Fm2\n* Hypertension (average resting blood pressure between 130\u002F80 mmHg and 160\u002F100 mmHg)\n\nExclusion Criteria:\n\n* Over 5 pack-years of smoking;\n* Prior shift work within 12 months prior to the study;\n* Travel greater than three time zones for at least 3 months;\n* History of heart failure, cardiomyopathy, or history of bypass surgery, angioplasty, or previous myocardial infarction;\n* Acute or chronic diseases (except hypertension) that may affect outcome measures;\n* History of psychological conditions;\n* Sleep disorders, like severe sleep apnea, insomnia, etc.;\n* Prescription medications (Contraceptives and anti-hypertensive medications are permissible);\n* History of Illicit drug use and alcohol dependency;\n* 30 days free of cannabis use prior to the study;\n* Pregnancy;\n* Upper cut-off of 160\u002F100 mmHg for BP","25 Years",{"count":226,"type":21},32,[54],"This study is a mechanistic clinical trial designed to investigate the effects of the circadian system and sleep on non-dipping blood pressure (BP) in people with hypertension (HTN).",[25,230,26,231,232],"Cardiovascular Diseases","Circadian Rhythms","Sleep",[234,235,236,237,238,239,240,241],"cardiovascular","circadian rhythms","sleep","blood pressure","constant routine","microneurography","hypertension","sleep regularization","2026-02-09",{"date":244,"type":35},"2026-02-11",{"date":246,"type":35},"2022-08-04",{"date":248,"type":21},"2029-03-30",{"name":250,"class":42},"Oregon Health and Science University",{"id":252,"slug":4,"hasResults":10,"nctId":253,"briefTitle":254,"officialTitle":255,"acronym":256,"eligibilityCriteria":257,"healthyVolunteers":10,"sex":17,"minAge":18,"maxAge":258,"enrollmentInfo":259,"targetDuration":4,"studyType":52,"phases":261,"briefSummary":262,"conditions":263,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":274,"lastUpdatePostDateStruct":275,"startDateStruct":277,"completionDateStruct":279,"leadSponsor":281,"locationsCount":4},"100621936","NCT07377097","Effects of Sweetener Consumption on Risk Factors for Heart Disease in Prediabetic Subjects","Effects of Sweetener Consumption on Risk Factors for Heart Disease","Sweetheart","Inclusion Criteria:\n\n* Presence of prediabetes (HbA1c 5.7-6.4% or glucose after oral glucose tolerance test 140 to 199 mg\u002FdL)\n* Written informed consent available\n\nExclusion Criteria:\n\n* Inability to communicate sufficiently in the required language\n* Dementia or other significantly cognitively impairing condition\n* Current pregnancy or breastfeeding\n* Other severe internal, neurological, or psychiatric condition\n* History of gout\n* History of gallstones \u002F diagnosis of cholelithiasis","75 Years",{"count":260,"type":21},80,[54],"The aim of this prospective interventional study is to investigate the metabolic effects of consuming artificial and natural sweeteners in persons with prediabetes. Prediabetes is a condition characterized by blood sugar levels that are elevated above normal but not yet meeting the criteria for type 2 diabetes. This condition markedly increases the risk of progressing to type 2 diabetes, which in turn can lead to complications including cardiovascular diseases.\n\nArtificial sweeteners such as saccharin and sucralose, as well as natural sugar substitutes like erythritol, are increasingly used as alternatives to sugar and are recommended for individuals at cardiometabolic risk - including overweight individuals, patients with prediabetes, or diabetics - to help reduce caloric intake. Recent literature has reported possible negative associations between artificial sweeteners and blood sugar regulation in healthy subjects (1). Additionally, effects on various blood cells have been observed. For example, erythritol has been shown to alter platelet function leading to increased reactivity in healthy study participants following consumption (2).\n\nHowever, the impact of alternative sweeteners on metabolic processes and their effects on blood coagulation in patients with prediabetes-a population at increased risk-has not been systematically studied. In this planned interventional study, 80 patients meeting laboratory criteria for prediabetes will be randomly assigned to one of four groups, each receiving a different intervention for two weeks: saccharin, sucralose, erythritol, or a control group receiving water. The doses reflect the acceptable daily intake or known doses that are considered safe.\n\nAfter enrollment, participants will visit the study center 2 times: before starting the intervention and after completing the intervention. During these visits, biological samples such as blood, urine, and stool will be collected to study metabolism, gut bacteria, immune and blood cell function. Tests will include an oral glucose tolerance test, coagulation tests, and additional blood analyses. Additionally, participants will wear a glucose monitor to track blood sugar fluctuations during the intervention.\n\nThe investigators hypothesize that consumption of alternative sweeteners negatively affects blood sugar regulation and insulin sensitivity in patients with prediabetes. Furthermore, this study will explore how the candidate sweeteners influence the gut microbiome, blood cells and other metabolic factors in this population.",[264,265,266,267,268,269,26,270,271,272,273],"Prediabetic State","Metabolic Syndrome","Insulin Resistance","Thrombosis","Hypercoagulable State","Cardiovascular (CV) Risk","Cardiovascular Diseases (CVD)","Prediabetes","Prediabetes \u002F Type 2 Diabetes","Sweeteners","2026-01-22",{"date":276,"type":35},"2026-01-29",{"date":278,"type":21},"2026-01-05",{"date":280,"type":21},"2026-11-01",{"name":97,"class":42},{"id":283,"slug":4,"hasResults":10,"nctId":284,"briefTitle":285,"officialTitle":286,"acronym":287,"eligibilityCriteria":288,"healthyVolunteers":10,"sex":17,"minAge":18,"maxAge":77,"enrollmentInfo":289,"targetDuration":4,"studyType":52,"phases":291,"briefSummary":292,"conditions":293,"keywords":295,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":301,"lastUpdatePostDateStruct":302,"startDateStruct":304,"completionDateStruct":306,"leadSponsor":308,"locationsCount":43},"100621446","NCT07370727","Velocity-Based Resistance Training in Kidney Transplant Recipients","Effects of Velocity-Based Resistance Training on Renal Function and Metabolic Health in Kidney Transplant Recipients: Protocol for a Randomized Controlled Trial","VBRTKIDNEY","Inclusion Criteria:\n\n* Men and women aged 18 to 50 years.\n* Kidney transplant performed ≥12 months before enrollment.\n* Stable graft function in the previous 6 months (serum creatinine \\\u003C 1.5 mg\u002FdL, no rejection episodes).\n* Written medical clearance from a nephrologist to perform moderate-to-vigorous physical activity.\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Active autoimmune disorders.\n* Recent coronary disease (≤6 months).\n* Severe musculoskeletal limitations incompatible with resistance training.\n* Diagnosis of diabetes mellitus (pre- or post-transplant).\n* Current active infection.\n* Use of immunosuppressive drugs with contraindications for exercise (e.g., mTOR inhibitors at baseline).",{"count":290,"type":21},12,[54],"This randomized controlled trial aims to evaluate the effects of velocity-based resistance training on renal function and metabolic health in kidney transplant recipients. Participants will be randomized into two groups performing resistance training at different execution velocities (maximal intended vs. submaximal controlled). The intervention will last 12 weeks and include multi-joint exercises (squat, bench press, military press). Primary outcomes include renal function (serum creatinine, eGFR, blood urea nitrogen, uric acid) and metabolic markers (HDL, triglycerides, glucose, waist circumference, blood pressure). Secondary outcomes include muscle strength, force-velocity profile, anthropometry, physical activity, fitness perception, and adherence to immunosuppressive medication.",[294,265,26],"Kidney Transplant Recipients",[296,297,298,111,299,300],"Kidney Transplant","Renal Transplant","Velocity based resistance training","Exercise Intervention","Glomerular Filtration Rate (eGFR)","2026-01-21",{"date":303,"type":35},"2026-01-27",{"date":305,"type":35},"2025-10-29",{"date":307,"type":21},"2027-12-31",{"name":309,"class":42},"Fundación Universitaria del Area Andina",{"id":311,"slug":4,"hasResults":10,"nctId":312,"briefTitle":313,"officialTitle":313,"acronym":314,"eligibilityCriteria":315,"healthyVolunteers":10,"sex":166,"minAge":316,"maxAge":317,"enrollmentInfo":318,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":320,"conditions":321,"keywords":325,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":334,"lastUpdatePostDateStruct":335,"startDateStruct":337,"completionDateStruct":339,"leadSponsor":341,"locationsCount":4},"100592890","NCT06999317","CARAMEL: Retrospective Study for Personalized Risk Assessment of Cardiovascular Disease in Menopausal and Perimenopausal Women Using Real World Data","CARAMEL RS","Inclusion Criteria:\n\nSelf-identified as female in the electronic health record (EHR). Age between 40 and 60 years at the time of data collection\u002Findex date. Availability of at least 5-6 years of retrospective data in the EHR, depending on the research objective.\n\nAt least one healthcare encounter (visit, imaging, lab test, diagnosis, etc.) within the defined age range.\n\nFor imaging substudies (e.g., RO3-RO5): availability of at least one relevant imaging test (e.g., DXA, digital mammography, cMRI, CCTA, US) during the age range.\n\nFor signal-based analysis (RO6): presence of ECG monitoring data from implanted devices and at least 2 years of follow-up.\n\nExclusion Criteria:\n\nPrior diagnosis of cardiovascular disease before the observation window (only applicable to specific ROs, e.g., RO2, RO4).\n\nInsufficient data quality or missing key variables needed for modeling (e.g., absence of blood pressure or lipid profile).\n\nPatients with incomplete or inconsistent records (e.g., duplicate IDs, mismatched time frames).\n\nFor signal-based RO6: hospitalizations or diagnoses unrelated to cardiovascular health that may bias AI model training.","40 Years","60 Years",{"count":319,"type":21},1500000,"This retrospective observational study, part of the EU-funded CARAMEL project, aims to develop and validate personalized cardiovascular disease (CVD) risk assessment models specifically designed for menopausal and perimenopausal women (ages 40-60). The study leverages Real World Data (RWD) collected from multiple international clinical partners, including electronic health records (EHR), diagnostic imaging data, and signal data.\n\nThe main objective is to improve the prediction of CVD precursors such as hypertension and dyslipidemia, as well as mid- and long-term risk of CVD events, through advanced artificial intelligence (AI) models. These models will be trained on multimodal data to capture complex, individualized risk trajectories that current risk calculators fail to address, particularly in women. Special focus is placed on under-researched, women-specific risk factors and their interactions with traditional predictors.\n\nThe study includes several research objectives: (1) predicting the onset of hypertension and dyslipidemia using EHR data; (2) modeling the long-term risk of fatal and non-fatal cardiovascular events and disease trajectories; (3) identifying novel imaging biomarkers from routine screening tests such as mammography, DXA, ultrasound, and cardiac MRI; (4) developing multimodal prediction models combining imaging and clinical data; (5) creating automated AI tools for imaging biomarker extraction; and (6) using signal data from cardiac devices to predict disease progression and events.\n\nThe study population consists of middle-aged women with retrospective data available across different health systems. The expected outcome is a validated set of stratified, personalized CVD risk models that can support targeted prevention strategies and enable more equitable, sex-specific care. This will contribute to reducing the burden of CVD in women and addressing critical gaps in early detection, clinical decision-making, and health policy.\n\nThis project has received funding from the European Union's Horizon Europe Research and Innovation Programme under Grant Agreement No 101156210.",[26,322,323,324],"Menopausal Women","Perimenopausal Women","Real World Data",[326,327,328,329,330,331,332,333],"Cardiovascular Disease","Cardiovascular risk factors","Menopausal women","Perimenopausal women","real world data","personalised prevention","computational modelling","women-specific risks","2026-01-13",{"date":336,"type":35},"2026-01-15",{"date":338,"type":21},"2026-03-01",{"date":340,"type":21},"2028-04-30",{"name":342,"class":42},"Hospital Universitario Virgen Macarena",{"id":344,"slug":4,"hasResults":10,"nctId":345,"briefTitle":346,"officialTitle":347,"acronym":348,"eligibilityCriteria":349,"healthyVolunteers":10,"sex":17,"minAge":350,"maxAge":4,"enrollmentInfo":351,"targetDuration":4,"studyType":52,"phases":353,"briefSummary":354,"conditions":355,"keywords":358,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":364,"lastUpdatePostDateStruct":365,"startDateStruct":367,"completionDateStruct":369,"leadSponsor":371,"locationsCount":43},"100586740","NCT06919302","The Effect of a Digital Heart Health App and Lifestyle Intervention for Heart Disease in Primary Care.","An Innovative Technology-based Approach to Translating Clinical Practice Guidelines of Nutrition Therapy in Primary Care: The Coronary Heart Effectiveness Assessment of the Portfolio Diet in Primary Care (CHEAP) Trial","CHEAP","Inclusion Criteria:\n\n* Be taking statin medication with or without other antihyperlipidemic therapy (stable dose for at least 3-months).\n* Fall under either of the 2 categories:\n\n  1\\) Secondary prevention participants: males and females ≥45 years of age with established atherosclerotic cardiovascular disease (ASCVD) defined as at least one of the following: i. Prior myocardial infarction (MI); ii. Acute coronary syndrome (ACS); iii. Stroke\u002FTIA; iv. Coronary revascularization; v. Documented carotid disease (endarterectomy, carotid stenosis ≥50%); vi. Stable angina; vii. Coronary artery disease (CAD) by angiography; viii. Peripheral artery disease (PAD); ix. Abdominal aortic aneurysm (AAA)\n\n  2\\) High-risk primary prevention participants: males and females ≥50 years of age plus type 2 diabetes requiring treatment with medication and at least one additional risk factor: i. Males ≥55 years of age and females ≥65 years of age; ii. Cigarette smoker or stopped smoking within 3 months before Visit 1; iii. Hypertension and on antihypertensive medication for at least 6-months; iv. Chronic kidney disease (CKD); v. Retinopathy, defined as any of the following: non-proliferative retinopathy, pre-proliferative retinopathy, proliferative retinopathy, maculopathy, advanced diabetic eye disease or a history of photocoagulation\n* Be on a stable dose for at least 3-months of all antihyperlipidemic, antihyperglycemic, antihypertensive, and antiobesity therapies.\n* Have a family physician in Ontario and a valid Ontario Health Card.\n* Have regular access to an online portal\n* Be proficient in English.\n\nExclusion Criteria:\n\n* Major disease expected to result in death within 2 years (except cardiovascular disease)\n* Active sever liver disease\n* Malabsorption disorders\n* Drug or alcohol abuse disorders (within past 6 months)\n* Intolerance or allergies to soy protein and tree nuts, peanuts, or seeds\n* Planned coronary intervention or any major surgical procedure\n* Participation in another clinical trial (within past 3 months)\n* End stage renal disease (requirement for peritoneal dialysis or hemodialysis for renal insufficiency or eGFR \\\u003C30 mL\u002Fmin)\n* Any condition or therapy which might pose a risk to the patient or make participation in the study not be in the best interest of the patient as assessed by the investigator\n* Documented severe (New York Heart Association \\[NYHA\\] class IV) heart failure\n* Mental\u002Fpsychological impairment expected to affect adherence to the study protocol\n* Known AIDS (HIV-positive patients without AIDS are allowed)\n* Women planning on becoming pregnant within the first year of the intervention\n* Unable to provide informed consent: Appear unable to comprehend the study protocol during the interview process or to understand and communicate in English sufficiently for informed consent.","45 Years",{"count":352,"type":21},1100,[54],"Despite the availability of medications, many people around the world continue to live with long-term health problems like heart disease, stroke and diabetes. In Canada, heart disease is a leading cause of death. Managing these health issues can be done by changing diet and lifestyle. Specific ways of eating have been proven to improve risk for heart disease and stroke. However, because doctors often have limited time, nutrition education, and lack of tools for counseling patients on nutrition, they can often only provide minimal support to help patients make necessary lifestyle changes. Digital tools and mobile applications offer an opportunity to involve doctors and patients in delivering nutrition interventions. This approach has the potential to save time, provide education, and reduce healthcare costs. This study is being done to understand the effect of a digital heart health program added to standard of care, compared with standard of care alone on heart health. All eligible participants in this study will be randomized (determined by chance) to one of two possible interventions: 1) a digital heart health program + standard of care; 2) standard of care. Standard is care is defined as the best practice based on guidelines for the treatment of a condition. All participants will be followed for seven years and will be asked to complete online questionnaires and complete blood work at their nearest LifeLabs clinic, as well as wear a continuous glucose monitor and wrist actigraph (at 3 time points in the first year). In addition, participants randomized to the digital heart health program + standard of care will be expected to use the heart health app and join 16 online synchronous sessions over the first year.\n\nAfter seven years, the intervention phase of the study will end and the study will become a cohort study. All participants at the 7-year time point will be invited to use the heart health app. As part of the cohort study, participants will be asked to continue completing the same questionnaires online and completing bloodwork at their nearest LifeLabs every four years for the duration of their participation in the cohort study.\n\nThe main questions this study aims to answer are:\n\n1. Will a digital heart health program added to standard of care result in a clinically meaningful reduction in blood cholesterol and other risk factors after 1-year compared to standard of care alone?\n2. Will a digital heart health program added to standard of care result in a reduction in major cardiovascular events after 7-years compared to standard of care alone?\n3. Are the observed effects sustained beyond the 7-years of the intervention?\n\nWe hypothesize that the digital heart health program added to standard of care will result in a clinically meaningful reduction in blood cholesterol and other risk factors for heart disease after 1-year and reduce major cardiovascular events after 7-years compared to standard of care alone.",[230,26,110,356,357],"Cholesterol","Major Cardiovascular Event",[359,360,361,362,363],"randomized controlled trial","digital heart health program","heart health app","web-based app","large-scale study","2025-11-20",{"date":366,"type":35},"2025-11-26",{"date":368,"type":35},"2025-08-15",{"date":370,"type":21},"2035-06-01",{"name":126,"class":42},{"id":373,"slug":4,"hasResults":10,"nctId":374,"briefTitle":375,"officialTitle":376,"acronym":4,"eligibilityCriteria":377,"healthyVolunteers":10,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":378,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":380,"conditions":381,"keywords":385,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":391,"lastUpdatePostDateStruct":392,"startDateStruct":394,"completionDateStruct":396,"leadSponsor":398,"locationsCount":43},"100596138","NCT07041554","Cardiovascular Risk Factors and Physical Activity in Chronic Kidney Patients on Peritoneal Dialysis","Examination of Cardiovascular Risk Factors and Physical Activity in Chronic Kidney Patients Treated With Peritoneal Dialysis","Inclusion Criteria:\n\n* Diagnosed with chronic kidney disease\n* Peritoneal dialysis treatment for at least three months\n* Age ≥ 18\n\nExclusion Criteria:\n\n* Mini Mental Test Score \\\u003C 24\n* Serious cardiovascular, pulmonary, or neurological conditions that make it impossible to wear an accelerometer\n* Inability to walk independently\n* Conditions affecting participation in daily life due to lower limb injury or surgery",{"count":379,"type":21},23,"The objective of this study was to examine the association between cardiovascular risk factors and physical activity parameters in patients with chronic kidney disease who are treated with peritoneal dialysis.",[382,26,383,384],"Chronic Kidney Diseases","Arterial Stiffness","Physical Activity",[386,387,388,389,390],"cardiovascular risk factors","physical activity","arterial stiffness","accelerometer","peritoneal dialysis","2025-06-18",{"date":393,"type":35},"2025-06-27",{"date":395,"type":21},"2025-06-23",{"date":397,"type":21},"2025-12-31",{"name":399,"class":42},"Dokuz Eylul University",{"id":401,"slug":4,"hasResults":10,"nctId":402,"briefTitle":403,"officialTitle":403,"acronym":4,"eligibilityCriteria":404,"healthyVolunteers":10,"sex":17,"minAge":316,"maxAge":405,"enrollmentInfo":406,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":408,"conditions":409,"keywords":410,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":415,"lastUpdatePostDateStruct":416,"startDateStruct":418,"completionDateStruct":420,"leadSponsor":422,"locationsCount":43},"100589077","NCT06949722","Redirecting Poor Sleep Drivers of Early Cardiovascular Disease","Inclusion Criteria:\n\n* Willing to wear a ring\n* Have any of the following conditions:\n\n  * High blood pressure\n  * High cholesterol\n  * Fatty liver\n  * Family history of heart diseases or stroke.\n  * Obesity\n\nExclusion Criteria:\n\n* Prior history of heart attack or stroke or balloon angioplasty\u002Fstent placement\n* Restricted peripheral circulation (e.g., Raynaud's disease)\n* Pacemakers","70 Years",{"count":407,"type":21},1500,"Sleep health is a critical component of cardiovascular well-being, and poor sleep has been linked with increased risk for all-cause mortality including cardiovascular disease (CVD). Moreover, many individuals within a population may have underlying, subclinical cardiovascular conditions, such as hypertension and arterial stiffness, and these may risk progressing to advanced CVD when coupled with inadequate sleep duration and quality. Given that Singapore ranks as the third most sleep-deprived city globally, understanding the relationship between sleep health and the prevalence and progression of CVD becomes increasingly important for population health. In addition, depression and psychological stress could also lead to poorer cardiovascular health by increasing blood cholesterol, blood sugar and blood pressure, and could also be directly related to or arise as a result of poor sleep. The aim of the current study is to track sleep and mental health using a combination of objective sleep tracking (Oura ring) and smartphone-based questionnaires (EMA), and examine their associations with detailed cardiovascular health data collected by the project RESET (Redirecting Immune, Lipid and Metabolic Drivers of Early Cardiovascular Disease).",[232,26],[232,411,412,413,414],"Cardiovascular disease","Wearables","Cardiovascular risk","Objective sleep tracking","2025-04-22",{"date":417,"type":35},"2025-04-29",{"date":419,"type":35},"2025-03-24",{"date":421,"type":21},"2027-12",{"name":423,"class":42},"National University of Singapore",{"id":425,"slug":4,"hasResults":10,"nctId":426,"briefTitle":427,"officialTitle":427,"acronym":428,"eligibilityCriteria":429,"healthyVolunteers":10,"sex":17,"minAge":18,"maxAge":430,"enrollmentInfo":431,"targetDuration":433,"studyType":22,"phases":4,"briefSummary":434,"conditions":435,"keywords":4,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":436,"lastUpdatePostDateStruct":437,"startDateStruct":439,"completionDateStruct":441,"leadSponsor":443,"locationsCount":445},"100452271","NCT05169333","The Oxford Risk Factors And Non-Invasive Imaging Study","ORFAN","Inclusion Criteria:\n\nInclusion Criteria for study Arms 1, 2 and 3:\n\n* Participant is willing and able to give informed consent for participation in the study.\n* Male or Female, aged 18 -99 years.\n\nInclusion Criteria for study Arm 4:\n\n• Male or Female, aged 18 -99 years.\n\nExclusion Criteria:\n\nExclusion Criteria for Study Arms 1, 2 and 3:\n\n* Unable or unwilling to consent\n* Active cancer\n\nExclusion Criteria for Study Arm 4:\n\n* Participation in Study Arms 1, 2 or 3\n* Existing opt-out from use of data for research purposes","99 Years",{"count":432,"type":21},250000,"15 Years","ORFAN is a prospective, multi-centre, multi-ethnic cohort observational study collecting CT scans, biological material and outcomes data, to develop and validate novel biomarkers of cardiometabolic and other disease risk.",[230,26],"2024-12-05",{"date":438,"type":35},"2024-12-11",{"date":440,"type":35},"2016-02-23",{"date":442,"type":21},"2030-02",{"name":444,"class":42},"University of Oxford",37,{"id":447,"slug":4,"hasResults":10,"nctId":448,"briefTitle":449,"officialTitle":450,"acronym":451,"eligibilityCriteria":452,"healthyVolunteers":10,"sex":17,"minAge":316,"maxAge":453,"enrollmentInfo":454,"targetDuration":4,"studyType":52,"phases":456,"briefSummary":457,"conditions":458,"keywords":4,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":462,"lastUpdatePostDateStruct":463,"startDateStruct":465,"completionDateStruct":467,"leadSponsor":469,"locationsCount":43},"100494970","NCT05725096","Role of Coronary CTA on Lipid Management and Risk Factors Control in an Asymptomatic Chinese Population","Role of the Screening with Coronary Computed Tomography Angiography on Lipid Management and Risk Factors Control in an Asymptomatic Chinese Population: a Community-based, Prospective Randomised Trial","RESPECT2","Inclusion Criteria:\n\n1. Nanjing residents who have no plans to leave in the next 5 years\n2. Aged from 40 to 69 years\n3. Free of any known clinically cardiovascular disease Able to comprehend and sign an informed consent form\n\nExclusion Criteria:\n\n1. Serious liver dysfunction, defined as AST or ALT \\> 3 times the normal upper limit\n2. Chronic kidney disease (CKD) \\> stage 4, defined as eGFR \\\u003C 30 ml\u002Fmin\u002F1.73 m2\n3. Prior CCTA or invasive coronary angiography within the last 5 years\n4. Any contraindications for CCTA\n5. Previous use of statin or non-statin lipid-lowering medication (such as ezetimibe, PCSK9 inhibitor and XueZhiKang)\n6. Life expectancy \\\u003C 3 years\n7. Other reasons the researcher deems inappropriate to attend","69 Years",{"count":455,"type":21},3400,[54],"The primary objective of this study is to determine whether coronary computed tomography angiography (CCTA) -based coronary heart disease(CHD) prevention strategy improves lipid-lowering treatment and cardiovascular risk factor control compared with traditional CHD prevention strategy, guided by a cardiovascular risk score.",[459,26,460,461],"Statin","Primary Prevention","Adherence, Medication","2024-11-25",{"date":464,"type":35},"2024-11-26",{"date":466,"type":35},"2023-06-28",{"date":468,"type":21},"2027-06",{"name":470,"class":42},"Zhang longjiang,MD",{"id":472,"slug":4,"hasResults":10,"nctId":473,"briefTitle":474,"officialTitle":475,"acronym":4,"eligibilityCriteria":476,"healthyVolunteers":10,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":477,"targetDuration":4,"studyType":52,"phases":479,"briefSummary":480,"conditions":481,"keywords":483,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":489,"lastUpdatePostDateStruct":490,"startDateStruct":492,"completionDateStruct":494,"leadSponsor":496,"locationsCount":43},"100513760","NCT05969665","Effect of Monitoring Continuous Glucose Levels and Physical Activity Via Wearables on Cardiovascular Risk Factors","Effect of Monitoring Continuous Glucose Levels and Physical Activity Via Wearables on Cardiovascular Risk Factors After Cardiac Rehabilitation - A Randomised Controlled Trial: MITIGATE-RF","Inclusion Criteria:\n\n* Informed Consent signed by the subject\n* Completed outpatient cardiac rehabilitation\n* Diagnosis of coronary heart disease\n* Access to a smartphone for the duration of the study\n* 18 years or older on the date of consent\n\nExclusion Criteria:\n\n* Diseases which limit physical activity including angina with incomplete revascularisation, arrhythmogenic cardiomyopathy, stroke with residual disease, and major orthopaedic disorders\n* Known or suspected non-compliance\n* Inability to follow the procedures of the investigation, e.g., due to language problems, psychological disorders, dementia, etc. of the subject\n* Diabetic patients receiving insulin therapy\n* Lack of proficiency with smart phone\u002Fwatch\n* Current participation in any other clinical trial, which may confound the results of this trial.\n* NYHA (New York Heart Association) class III or IV congestive heart failure\n* Pregnancy",{"count":478,"type":21},100,[54],"The study aims to assess the effect of smart watches and continuous glucose measuring devices on cardiovascular risk factors.",[482,384,26],"Coronary Heart Disease",[237,484,485,486,487,488],"lipids","glucose level","smoking","weight","diet","2024-08-13",{"date":491,"type":35},"2024-08-14",{"date":493,"type":35},"2024-02-07",{"date":495,"type":21},"2025-08",{"name":497,"class":42},"University Hospital, Basel, Switzerland",{"id":499,"slug":4,"hasResults":10,"nctId":500,"briefTitle":501,"officialTitle":501,"acronym":4,"eligibilityCriteria":502,"healthyVolunteers":16,"sex":17,"minAge":503,"maxAge":4,"enrollmentInfo":504,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":506,"conditions":507,"keywords":4,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":508,"lastUpdatePostDateStruct":509,"startDateStruct":511,"completionDateStruct":513,"leadSponsor":515,"locationsCount":517},"100230833","NCT02282748","Swiss Longitudinal Cohort","Inclusion Criteria:\n\n* Resident of Cama GR, Lostallo GR, or Uznach SG\n* Age ≥6 years (no upper age limit), for voluntary blood sample ≥18 years\n* Willing to participate in long-term study\n* Written informed consent (in participants ≥6 years and \\\u003C18 years signed by parents)\n\nExclusion Criteria:\n\n* No exclusion criteria","6 Years",{"count":505,"type":21},1000,"The planned research project is a prospective population-based cohort study, similar to the well-known Framingham study in the United States. So far, there is no similar research project in Switzerland.\n\nIt is planned to examine of three Swiss municipalities. Recruitment in a first Swiss municipality (Lostallo\u002FCama GR) started 2014 and ended in 2019. Overall, 496 participants were recruited in this municipality. The five-year follow-up in this municipality started in 2019. It is planned to start recruitment in a second Swiss municipality (Uznach SG) in 2020.\n\nThe examinations embrace a broad spectrum of measurements (for details the investigators refer to the published study protocol).",[26],"2020-02-14",{"date":510,"type":35},"2020-02-18",{"date":512,"type":4},"2014-10",{"date":514,"type":21},"2034-09",{"name":516,"class":42},"Hypertension Excellence Centre Lucerne",3,{"id":519,"slug":4,"hasResults":10,"nctId":520,"briefTitle":521,"officialTitle":522,"acronym":523,"eligibilityCriteria":524,"healthyVolunteers":10,"sex":17,"minAge":134,"maxAge":4,"enrollmentInfo":525,"targetDuration":526,"studyType":22,"phases":4,"briefSummary":527,"conditions":528,"keywords":538,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":542,"lastUpdatePostDateStruct":543,"startDateStruct":545,"completionDateStruct":547,"leadSponsor":549,"locationsCount":4},"100251946","NCT02558452","European Transplant Registry of Senior Renal Transplant Recipients on Advagraf","European Transplant Registry of Senior Renal Transplant Recipients Receiving Initial Immunosuppression With Tacrolimus Once Daily, Mycophenolate and Steroids","SENIOR","Inclusion Criteria:\n\n* Males or females, aged ≥65 years\n* Patients who received a renal allograft\n* Patients who are willing and able to participate in the study and from whom written informed consent has been obtained\n* Patients on an intended standard triple therapy with tacrolimus once daily (Advagraf with trough level ≥5ng\u002Fml) in combination with mycophenolate (either ≥1.0g\u002Fday MMF or ≥720mg\u002Fd EC-MPS) and Steroids (≥5mg prednisolone or equivalent)\n* Patient must have received primary or secondary renal allograft from a blood group compatible donor (either deceased or living)\n* Patients with low to standard immunological risk, who had a PRA 20% (PRA testing according to center's practice) or no known donor specific antibodies at transplantation\n\nExclusion Criteria:\n\n* Multi-organ recipients (solid organ or bone marrow)\n* More than secondary renal allograft recipients\n* Blood group A,B,O-incompatible allografts\n* Documented presence of donor specific antibodies (DSA)\n* Panel reactive antibody (PRA) \\>20% prior to transplantation (PRA testing according to center's practice)\n* Patients having received any other induction therapy than Basiliximab or depleting polyclonal antithymocyte antibodies (ATG) (e.g. OKT3, Campath)\n* Patients receiving Sirolimus, Everolimus, Azathioprine, Belatacept or Cyclophosphamide within 3 months prior to or at enrolment\n* History of alcohol or drug abuse with less than 6 months of sobriety\n* Patient with any condition that may affect absorption of immunosuppressives, (e.g. severe diarrhoea, gastrectomy, active peptic ulcer disease or clinically significant diabetic gastroenteropathy) or tacrolimus metabolism (e.g. liver cirrhosis)\n* Patient with mental dysfunction or inability to cooperate within the study\n* Patients who have been institutionalized by official or court order",{"count":505,"type":21},"10 Years","SENIOR transplant Registry European transplant registry of senior renal transplant recipients (above the age of 65 years) receiving initial immunosuppression with tacrolimus once daily, mycophenolate and steroids to investigate long term outcomes on an observational basis.",[529,530,531,532,533,534,535,536,26,537],"Graft Failure","Death","Acute Rejection of Renal Transplant","Infections","Bone Disease","Post Transplant Diabetes Mellitus","Quality of Life","HLA Antibody Production","Non-HLA Antibody Production",[539,540,541],"elderly kidney transplant recipient","registry","tacrolimus once daily","2016-08-11",{"date":544,"type":21},"2016-08-12",{"date":546,"type":4},"2016-12",{"date":548,"type":21},"2028-01",{"name":550,"class":42},"Klemens Budde",""]